odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
5113
10.69690/ODMJ-002-0912-5113
Reviews
Muscle-Invasive Bladder Cancer: Evolving Therapies and Real-World Access Gaps in Turkey
Coşkunpınar
Muharrem
Department of Medical Oncology, Ankara University School of Medicine
https://orcid.org/0000-0003-4093-5436
Süer
Evren
Department of Urology, Ankara University School of Medicine
https://orcid.org/0000-0002-9152-9887
Ürün
Yüksel
Department of Medical Oncology, Ankara University School of Medicine
yukselurun@gmail.com
12
09
2025
ODMJ-002-0912-5113
Copyright (c) 2025 OncoDaily Medical Journal
2025
OncoDaily Medical Journal
bladder cancer
production-ready-file-url
[
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.
]
[
Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nat Rev Dis Primers. 2023;9(1):58.
]
[
Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75-94.
]
[
Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82-104.
]
[
Gschwend JE, Heck MM, Lehmann J, Rubben H, Albers P, Wolff JM, et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol. 2019;75(4):604-11.
]
[
Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner EC, et al. SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer. J Clin Oncol. 2023;41(16).
]
[
Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, Herr HW, et al. Validating a local failure risk stratification for use in prospective studies of adjuvant radiation therapy for bladder cancer. Int J Radiat Oncol Biol Phys. 2016;95(2):703-6.
]
[
Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, et al. Development and validation of consensus contouring guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy. Int J Radiat Oncol Biol Phys. 2016;96(1):78-86.
]
[
Zaghloul MS, Christodouleas JP, Smith A, Abdallah A, William H, Khaled HM, et al. Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after radical cystectomy: a randomized phase 2 trial. JAMA Surg. 2018;153(1):e174591.
]
[
Peak TC, Hemal A. Partial cystectomy for muscle-invasive bladder cancer: a review of the literature. Transl Androl Urol. 2020;9(6):2938-45.
]
[
James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477-88.
]
[
Gupta S, Fujii Y, van der Heijden MS, Weickhardt AJ, James ND, Shariat SF, et al. Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2024;42(4):TPS720-TPS.
]
[
Singh P, Tangen C, Efstathiou JA, Lerner SP, Jhavar SG, Hahn NM, et al. INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806. J Clin Oncol. 2020;38(6).
]
[
International Collaboration of T, MRC Advanced Bladder Cancer Working Party, EORTC GU Group, Australian Bladder Cancer Study Group, NCIC Clinical Trials Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171-7.
]
[
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-66.
]
[
Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48(2):202-5.
]
[
Bajorin DF, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;385(9):864-74.
]
[
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525-37.
]
[
Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432-7.
]
[
Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med. 2025;392(1):45-55.
]
[
Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391(19):1773-86.
]
[
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875-88.
]
[
Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066-73.
]
[
Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven-year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42(1):50-4.
]
[
Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988;318(22):1414-22.
]
[
von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602-8.
]
[
De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191-9.
]
[
Gupta S, Bellmunt J, Plimack ER, Sonpavde GP, Grivas P, Apolo AB, et al. Defining platinum-ineligible patients with metastatic urothelial cancer. J Clin Oncol. 2022;40(16_suppl):4577.
]
[
National Comprehensive Cancer Network. NCCN guidelines: bladder cancer. Version 1.2025 [Internet]. Plymouth Meeting (PA): NCCN; 2025 [updated 2025 Jul 29; cited 2025 Aug 25].
]
[
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35(6):485-90.
]
[
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778-89.
]
[
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218-30.
]
[
Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ullen A, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up. J Clin Oncol. 2023;41(19):3486-92.
]
[
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015-26.
]
[
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961-71.
]
[
Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonzalez-Martin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47-58.
]
[
Antar RM, Xu VE, Adesanya O, Drouaud A, Longton N, Gordon O, et al. Income disparities in survival and receipt of neoadjuvant chemotherapy and pelvic lymph node dissection for muscle-invasive bladder cancer. Curr Oncol. 2024;31(5):2566-81.
]
[
The World Bank. The World Bank in Türkiye [Internet]. Washington (DC): The World Bank; c2025 [updated 2025 Apr 24; cited 2025 Aug 25].
]
[
Tural D, Özkan O, Yaslikaya S, Tatli AM, Akdag G, Demir H, et al. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program (EAP). J Clin Oncol. 2025;43(5_suppl).
]
[
Herchenhorn D, Freire V. Access of new systemic therapies for genito-urinary cancers in low-middle income countries. Front Urol. 2022;2:1-8.
]